Earnings call transcript: WuXi AppTec beats Q3 2025 expectations

WuXi AppTec reported strong Q3 2025 financial results, significantly surpassing analyst expectations with an EPS of $1.24 and revenue of $12.06 billion, driven by a 22.5% year-over-year revenue increase from continuing operations and a 121.1% surge in its TIDES business. Following the announcement, the stock price rose by 3.36%. The company raised its full-year revenue guidance to RMB 43.5-44.0 billion and free cash flow to RMB 8.0-8.5 billion, while also announcing the divestiture of its China-based clinical research services business to sharpen focus on its core CRDMO model and accelerate global capacity expansion in locations like Singapore and the U.S.

Analysis

WuXi AppTec reported exceptionally strong Q3 2025 financial results, significantly surpassing analyst expectations with an EPS of $1.24 against a forecast of $1.04, and revenue of $12.06 billion exceeding the anticipated $11.52 billion. This robust performance, marked by a 22.5% year-over-year revenue increase from continuing operations and a 121.1% surge in its TIDES business, propelled the stock price up by 3.36% post-announcement, reflecting investor optimism. The company maintains a "GREAT" financial health score of 3.35 and is considered undervalued by InvestingPro's Fair Value.

The company has strategically raised its full-year revenue guidance to RMB 43.5-44.0 billion and increased its free cash flow projection to RMB 8.0-8.5 billion, signaling confidence in future prospects. Concurrently, WuXi AppTec announced the divestiture of its China-based clinical research services business, which contributed 3.5% of Q1-Q3 2025 revenue, to sharpen its focus on the higher-margin core CRDMO model. This move is expected to enhance overall profitability and operational efficiency.

Growth is further underpinned by a record backlog of RMB 59.88 billion, up 41.2% year-over-year, primarily driven by the small molecule DNM and TIDES segments. To mitigate geopolitical risks and meet growing customer demand, the company is actively accelerating global capacity expansion, with new facilities planned in Singapore and the U.S., alongside expansions in Switzerland. This diversified geographical footprint aims to ensure stability and resilience in its financial performance.

Despite the positive outlook, potential regulatory changes in the U.S. biotech sector, such as the BioSecure bill, remain a key risk, though current legislative drafts do not specifically name WuXi AppTec. The company also demonstrated a strong commitment to shareholder returns, having implemented RMB 6.88 billion in cash dividends and share repurchases, representing over 70% of its 2024 net profit.

Key Decisions for Investors

• Monitor the progress of U.S. biotech regulatory legislation for potential impacts on global operations, Evaluate the effectiveness of the company's accelerated global capacity expansion in mitigating geopolitical risks and driving future growth, Assess the long-term margin benefits and strategic focus resulting from the divestiture of the clinical research services business, Consider the sustainability of the strong backlog and operating cash flow growth as indicators of continued robust performance.